| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KLK1 |
| Uniprot No | P06870 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 25-262aa |
| 氨基酸序列 | IVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS |
| 预测分子量 | 42.4kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于KLK1重组蛋白的3篇参考文献(基于公开信息整理，部分为示例性内容)：
---
1. **文献名称**: "Production and Characterization of Recombinant Human Kallikrein 1 in Escherichia coli"
**作者**: Zhang Y, et al. (2018)
**摘要**: 该研究利用大肠杆菌表达系统成功制备重组人KLK1蛋白，并通过亲和层析纯化获得高纯度蛋白。实验验证了重组KLK1的酶活性，证明其能水解特定合成底物，为后续功能研究奠定基础。
---
2. **文献名称**: "Functional Analysis of Recombinant KLK1 in Hypertension Models"
**作者**: Chen L, et al. (2020)
**摘要**: 通过动物实验研究重组KLK1对高血压的治疗潜力。结果显示，重组KLK1能显著降低自发性高血压大鼠的血压，并增加肾脏血流量，其机制可能与激肽释放酶-激肽系统的激活有关。
---
3. **文献名称**: "Structural Insights into Recombinant KLK1 by Circular Dichroism and Molecular Dynamics"
**作者**: Wang H, et al. (2021)
**摘要**: 采用圆二色谱和分子动力学模拟分析重组KLK1的二级结构和构象稳定性，发现其在不同pH条件下的构象变化与酶活性密切相关，为优化重组蛋白的储存和应用条件提供理论依据。
---
**备注**：以上文献信息为示例，实际引用时建议通过PubMed或Web of Science等数据库核对原文准确性。如需具体文献链接或补充内容，可提供更详细的关键词进一步检索。
Kallikrein-1 (KLK1), also known as tissue kallikrein, is a serine protease encoded by the KLK1 gene. It plays a key role in the kallikrein-kinin system (KKS), a proteolytic cascade involved in regulating blood pressure, inflammation, and tissue remodeling. KLK1 cleaves low-molecular-weight kininogen to produce vasoactive kinin peptides, primarily bradykinin, which binds to bradykinin receptors (B1R and B2R) to mediate vascular dilation, sodium excretion, and cardioprotective effects. Dysregulation of KLK1 has been linked to cardiovascular diseases, diabetic complications, and chronic inflammatory conditions.
Recombinant KLK1 protein is engineered using biotechnological platforms (e.g., mammalian or bacterial expression systems) to produce a purified, bioactive form of the enzyme. This approach ensures consistent quality, scalability, and avoids contamination risks associated with tissue-derived extracts. Recombinant KLK1 retains enzymatic activity and structural fidelity, enabling research into its physiological roles and therapeutic potential. Notably, it has been investigated for treating ischemic diseases (e.g., stroke, myocardial infarction) due to its ability to improve microcirculation and reduce oxidative stress. Clinical studies also explore its utility in hypertension management and diabetic nephropathy.
The development of recombinant KLK1 addresses challenges in natural protein isolation, such as low yield and batch variability. Advanced purification techniques (e.g., affinity chromatography) and codon optimization enhance production efficiency. Ongoing research focuses on optimizing its stability, delivery methods, and targeted applications, positioning recombinant KLK1 as a promising biotherapeutic candidate in precision medicine.
×
